Literature DB >> 10565933

Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut.

F C Tenover1, M J Mohammed, T S Gorton, Z F Dembek.   

Abstract

Extended-spectrum beta-lactamases (ESBLs) are enzymes produced in some gram-negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam. They are most common in Klebsiella spp. and Escherichia coli but are present in a variety of Enterobacteriaceae. Resistance mediated by these enzymes can be difficult to detect depending on the antimicrobial agents tested. AmpC beta-lactamases are related to the chromosomal enzymes of Enterobacter and Citrobacter spp. and also mediate resistance to extended-spectrum cephalosporins and aztreonam in addition to cephamycins, such as cefoxitin. Unlike ESBLs, however, AmpC beta-lactamases are not inhibited by clavulanic acid or other similar compounds. To assess the abilities of various antimicrobial susceptibility testing methods to detect ESBLs, we sent three ESBL-producing organisms, one AmpC-producing organism, and a control strain that was susceptible to extended-spectrum cephalosporins to 38 laboratories in Connecticut for testing. Eight (21.0%) of 38 labs failed to detect extended-spectrum cephalosporin or aztreonam resistance in any of the ESBL- or AmpC-producing isolates. Errors were encountered with both automated and disk diffusion methods. Conversely, seven (18.4%) labs categorized at least some of the four resistant isolates as potential ESBL producers and reported the results with the extended-spectrum cephalosporins and aztreonam as resistant as suggested by current National Committee for Clinical Laboratory Standards (NCCLS) guidelines. The percentage of laboratories that failed to detect resistance in the ESBL or AmpC isolates ranged from 23.7 to 31.6% depending on the type of enzyme present in the test organism. This survey suggests that many laboratories have difficulty detecting resistance in ESBL and AmpC-producing organisms and may be unaware of the NCCLS guidelines on modifying susceptibility testing reports for ESBL-producing strains.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565933      PMCID: PMC85882     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.

Authors:  E Vercauteren; P Descheemaeker; M Ieven; C C Sanders; H Goossens
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 4.  Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.

Authors:  A A Medeiros
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

5.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

Review 6.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

7.  Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases.

Authors:  G P Katsanis; J Spargo; M J Ferraro; L Sutton; G A Jacoby
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

8.  Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase.

Authors:  G L French; K P Shannon; N Simmons
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

9.  Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.

Authors:  J Wiener; J P Quinn; P A Bradford; R V Goering; C Nathan; K Bush; R A Weinstein
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

10.  Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa.

Authors:  P Nordmann; E Ronco; T Naas; C Duport; Y Michel-Briand; R Labia
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  35 in total

1.  Plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem.

Authors:  H Yano; A Kuga; R Okamoto; H Kitasato; T Kobayashi; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Authors:  Christine C Sanders; Anton F Ehrhardt; Ellen Smith Moland; Kenneth S Thomson; Barbara Zimmer; Darcie E Roe
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

3.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Molecular characterization of extended-spectrum beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey.

Authors:  Mariagrazia Perilli; Emanuela Dell'Amico; Bernardetta Segatore; Maria Rosaria de Massis; Ciro Bianchi; Francesco Luzzaro; Gian Maria Rossolini; Antonio Toniolo; Giuseppe Nicoletti; Gianfranco Amicosante
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

Review 5.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals.

Authors:  Ellen Smith Moland; Jennifer A Black; Jason Ourada; Mark D Reisbig; Nancy D Hanson; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

7.  Extended-spectrum beta-lactamases in Ireland, including a novel enzyme, TEM-102.

Authors:  Dearbháile Morris; Colette O'Hare; Maura Glennon; Majella Maher; Geraldine Corbett-Feeney; Martin Cormican
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

8.  Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world.

Authors:  Christine Lascols; Meredith Hackel; Andrea M Hujer; Steven H Marshall; Sam K Bouchillon; Daryl J Hoban; Stephen P Hawser; Robert E Badal; Robert A Bonomo
Journal:  J Clin Microbiol       Date:  2012-02-08       Impact factor: 5.948

9.  Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in Gram-negative isolates.

Authors:  Andrea Endimiani; Andrea M Hujer; Kristine M Hujer; Julian A Gatta; Andrew C Schriver; Michael R Jacobs; Louis B Rice; Robert A Bonomo
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

10.  Evaluation of the current National Committee for Clinical Laboratory Standards guidelines for screening and confirming extended-spectrum beta-lactamase production in isolates of Escherichia coli and Klebsiella species from bacteremic patients.

Authors:  O T Katz; N Peled; P Yagupsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-08       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.